Supplied medicines to approximately 1 billion
patients globally
PITTSBURGH, May 16, 2023
/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare
company, today published its 2022 Sustainability Report showcasing
its commitment, impact and progress on building sustainable access
to medicine as it continues to make a positive difference across
key areas including Access and Global Health, Our People, the
Environment and the Community.
Viatris supplied medicines to approximately
1 billion patients globally in 2022
"At Viatris, access is fundamental to our mission of empowering
people worldwide to live healthier at every stage of
life," said Scott A. Smith,
CEO, Viatris. "It begins with our ability to sustainably deliver
high-quality medicines and health solutions at scale to people,
regardless of geography or circumstance. Our commitment is both
practical and aspirational and goes beyond developing, making and
distributing medicines. We also work with partners to help support
healthy communities, a healthy environment and resilient healthcare
systems. The passion and dedication of our global workforce is
remarkable and clearly on display in this report, which highlights
the progress we are making to build more sustainable access to
medicine across the globe."
Viatris is a signatory to the United Nations Global Compact
(UNGC) and is committed to the Compact's 10 principles related to
human rights, labor, the environment and anti-corruption and
supports the Sustainable Development Goals.
The following are some highlights of Viatris' work and
initiatives across its multiple areas of impact in 2022:
Access and Global Health
- Supplied medicines to approximately 1 billion patients
globally.
- Provided treatments for approximately 8 million people
living with HIV/AIDS, including almost 600,000 children.
- Provided >250 medicines on the World Health
Organization (WHO) Essential Medicines List and 62 products on the
WHO Pre-Qualification List.
- Promoted and strengthened healthcare professional
education and training to build more resilient healthcare systems
and address the burden of non-communicable diseases (NCDs), which
account for nearly 75% of global deaths annually. More than 300
million patients were impacted by Viatris' outreach to healthcare
professionals in 2022.
Our People
- Conducted our first global Viatris Voice Survey with a
participation rate of 89%. The baseline survey marked a milestone
in our commitment to engage colleagues by listening to their
perspectives on overall engagement; diversity, equity and
inclusion; health and wellbeing; and transformation and
change.
- Named one of Forbes' World's Best Employers for 2022,
ranking in the top 10% of the 800 employers who made the list.
The Environment
- Committed to reduce absolute scope 1 and 2 greenhouse
gas emissions 42% by 2030 from a 2020 base year and further, to
reduce absolute Scope 3 greenhouse gas emissions covering purchased
goods and services, capital goods, fuel and energy related
activities, and upstream transportation and distribution 25% within
the same timeframe.
- Received validation and approval of Viatris' scope 1, 2
and 3 greenhouse gas emissions reduction targets from the Science
Based Targets initiative (SBTi). The SBTi classified Viatris' scope
1 and 2 target ambition and has determined that it is in line with
the 1.5°C trajectory.
- Performed five water risk assessments — four in
facilities in India and one in
Türkiye.
- Increased the number of zero-waste landfill locations to
a total of 16.
The Community
- Donated more than 450 million doses of medicines through
our partners around the world and provided a total of $1 million to aid in supporting access to
healthcare, food security and water stewardship to four
organizations: Direct Relief, World Central Kitchen (WCK), WaterAid
and World Food Program USA,
partner of the United Nations World Food Programme.
- Supported communities across the globe, including
helping to evacuate and relocate people at the onset of the
conflict in Ukraine and provided
funds, medical donations and supplies to communities
devastated by the earthquakes in parts of Türkiye and Syria in February
2023.
"We understand our conduct and actions affect the stakeholders
and communities we serve," said Lara
Ramsburg, Head of Corporate Affairs of Viatris. "We are
proud to continue our work as a trusted partner of key stakeholders
as we help to close gaps to equal access to care, build more
resilient healthcare systems, uphold a reliable global supply of
medicines, curb climate change and protect the environment."
Viatris is dedicated to transparent annual reporting on
environmental, social and governance matters, continuously working
to further enhance its disclosures. Click here to view more
information or to read our 2022 Sustainability Report.
About Viatris
Viatris Inc. (NASDAQ: VTRS)
is a global healthcare company empowering people worldwide to live
healthier at every stage of life. We provide access to medicines,
advance sustainable operations, develop innovative solutions and
leverage our collective expertise to connect more people to more
products and services through our one-of-a-kind Global Healthcare
Gateway®. Formed in November 2020,
Viatris brings together scientific, manufacturing and distribution
expertise with proven regulatory, medical, and commercial
capabilities to deliver high-quality medicines to patients in more
than 165 countries and territories. Viatris' portfolio comprises
more than 1,400 approved molecules across a wide range of
therapeutic areas, spanning both non-communicable and infectious
diseases, including globally recognized brands, complex generic and
branded medicines and a variety of over-the-counter consumer
products. With more than 38,000 colleagues globally, Viatris is
headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com
and investor.viatris.com, and connect with us on Twitter at
@ViatrisInc, LinkedIn, Instagram and YouTube.
Forward-looking Statements
This press release includes statements that constitute
"forward-looking statements." These statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward looking statements may include
statements about our sustainability goals and initiatives. Factors
that could cause or contribute to such differences include, but are
not limited to: the possibility that the Company may be unable to
realize the intended benefits of, or achieve the intended goals or
outlooks with respect to, its strategic initiatives; the
possibility that the Company may be unable to achieve expected
benefits, synergies and operating efficiencies in connection with
acquisitions, divestitures, or its global restructuring program,
within the expected timeframe or at all; impairment charges or
other losses related to the divestiture or sale of businesses or
assets; the Company's failure to achieve expected or targeted
future financial and operating performance and results; the
potential impact of public health outbreaks, epidemics and
pandemics, including the ongoing challenges and uncertainties posed
by COVID-19; actions and decisions of healthcare and pharmaceutical
regulators; changes in healthcare and pharmaceutical laws and
regulations in the U.S. and abroad; any regulatory, legal or other
impediments to Viatris' ability to bring new products to market,
including but not limited to "at-risk" launches; Viatris' or its
partners' ability to develop, manufacture, and commercialize
products; the scope, timing and outcome of any ongoing legal
proceedings, and the impact of any such proceedings; any
significant breach of data security or data privacy or disruptions
to our information technology systems; risks associated with
international operations; the ability to protect intellectual
property and preserve intellectual property rights; changes in
third-party relationships; the effect of any changes in Viatris' or
its partners' customer and supplier relationships and customer
purchasing patterns; the impacts of competition; changes in the
economic and financial conditions of Viatris or its partners;
uncertainties and matters beyond the control of management,
including general economic conditions, inflation and exchange
rates; failure to execute stock repurchases consistent with current
expectations; stock price volatility; and the other risks described
in Viatris' filings with the Securities and Exchange Commission
(SEC). Viatris routinely uses its website as a means of disclosing
material information to the public in a broad, non-exclusionary
manner for purposes of the SEC's Regulation Fair Disclosure (Reg
FD). Viatris undertakes no obligation to update these statements
for revisions or changes after the date of this release other than
as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viatris-publishes-sustainability-report-showcasing-2022-progress-on-building-sustainable-access-to-medicine-301825900.html
SOURCE Viatris Inc.